Biggest Stock Movers Monday: RNA, HIVE, and More
Stock futures edged higher in Monday’s premarket session as optimism over a potential US-China trade deal and a widely expected Federal Reserve rate cut lifted sentiment. Investors are also bracing for a flood of Big Tech earnings, with the week set to be active on the earnings front.
Quick Insights
The acquisition expands Novartis’s pipeline in rare muscle disorders and strengthens its position in genetic and rare disease therapies ahead of key patent expirations.
HIVE has surpassed 22 exahash per second (EH/s) in computing power, targeting 25 EH/s. This growth is expected to boost HIVE’s revenue and cash flow, with management highlighting that these metrics drive digital infrastructure valuations.
Additionally, recent capital raises will support targeted acquisitions, research and development scale-up, and business expansion. POET’s pro forma cash position will increase to over $300 million, enabling further growth initiatives.
Recommended For You
More Trending News
